fbpx

Category: Uncategorized

Contact Us

Contact us on 1300 369 772 Monday to Friday, business hours

Share this page

Changes to membership renewals FAQs

When will automatic renewal start?
Automatic renewal will begin after your next membership cycle. Your upcoming renewal will be processed as normal.

 

Will I be notified before my membership renews automatically?
Yes. You’ll receive reminder emails 30 days and 14 days before your renewal date, giving you time to review your membership and payment options.

 

Can I opt out of automatic renewal?
If you prefer to renew manually each year, you can opt out anytime via your PSA Member Portal.

 

How do I update my payment details?
You can securely update your payment details by logging into your PSA Member Portal. This gives you more control over how you pay.

 

What happens if my payment fails during automatic renewal?
If a payment fails, our Member Services Team will contact you to help resolve the issue and ensure your membership continues without interruption.

 

Will my membership benefits change with automatic renewal?
No, your membership will renew with the same benefits, products, and payment instalment plan you currently have. If you are on our Essential (concession) membership tier, you may be asked to complete a short declaration to confirm that you still meet the eligibility criteria.

 

What does this mean if I pay my membership monthly? 

Your payments will continue to be deducted from your preferred payment method monthly. You can update your payment details at any time through your member portal.

 

Who can I contact if I have questions or need help?
Our friendly Member Services Team is here to help. You can reach us at membership@psa.org.au or call 1300 369 772.

Share this page
Share this page

Code of Ethics review

July 2025 to June 2026

The Pharmaceutical Society of Australia (PSA), in partnership with the Department of Health, Disability and Ageing, is undertaking a review, update and further development of the Code of Ethics for Pharmacists (the ‘Code’).  The Code is a fundamental resource that articulates the values of the pharmacy profession and expected standards of ethical behaviour of pharmacists towards individuals, the community and society. The Code underpins the professional practice of all pharmacists in Australia.

 

The core objectives are to:

  • review, revise and further develop the Code to align with contemporary pharmacy practice and the expectations of the profession and the wider community
  • deliver a revised Code with increased clarity on emerging ethical issues (e.g. broadening scope of practice, increased compounding, expansion of digital systems that provide clinical information to pharmacists)
  • support pharmacists to implement the revised Code to enable pharmacists to continue to provide the highest quality of care in their daily practice.

This project commenced on 1st July 2025 and will conclude 30th June 2026. Key dates:

  • July – October 2025 – Stakeholder Engagement & Consultation
  • March – April 2026 – Public Consultation of the revised Code draft
  • June 2026 – Launch of revised Code
  • July 2026 – National Webinar

Stakeholder engagement and consultation

Have your say – join a PSA Workshop

The Pharmaceutical Society of Australia (PSA) is inviting expressions of interest from registered pharmacists to join one of three Code of Ethics Workshops.

 

Each workshop will focus on one of the existing ethical values and their associated principles – Care, Integrity, or Competency – to ensure they remain relevant, practical, and aligned with contemporary pharmacy practice.

 

These once-only 1.5-hour virtual workshops are part of the stakeholder consultation for the review, revision, and further development of the Code of Ethics for Pharmacists. They will be facilitated by PSA and subject matter experts, offering a collaborative environment to share insights, discuss challenges, and shape the future of pharmacy ethics in Australia.

→ Workshop Dates:
  • Care: Tuesday 30 September 2025 – 12:30pm–2:00pm AEST
  • Integrity: Wednesday 1 October 2025 – 1:00pm–2:30pm AEST
  • Competency: Thursday 2 October 2025 – 11:30am–1:00pm AEST

 

→ Important:
  • Workshops are capped at 10 participants each.
  • We will score each application using a rubric weighted criteria and use the resulting total scores to rank applicants and determine the order in which workshop places are offered.
  • While you may express interest in multiple working groups, please note that you may be selected to join only one.

 

To express your interest and nominate your preferred workshop, complete the EOI Form here. If selected to participate, pharmacists can claim unaccredited 1.5 Group 1 CPD credits.

This EOI closes Wednesday 17th September 2025 – don’t miss this opportunity to contribute to the review and refinement of the PSA Code of Ethics and help guide the profession into the future.

Profession Survey – Your Ethics, your voice

This survey invites pharmacists to share their views on current and emerging ethical issues in pharmacy practice. The feedback collected will help inform the review and revision of the current Code of Ethics to ensure it reflects the values, challenges, and responsibilities of contemporary pharmacy practice.

 

To complete the survey, please access it here. This survey will close 5pm Friday 10th October 2025.

Book in a semi structured consultation discussion with PSA (30 mins)

Consultations will run between 25th August 2025 and 3rd October 2025. To book a suitable time as an organisation or individual please email PSA Project Manager – Leah.Robinson@psa.org.au.

Have feedback or insights outside of these options?

You can either submit the form below or call 1300 369 772 and select “Code of Ethics review project”, leave a message and the PSA team will contact you.

SUBMIT FEEDBACK

From the President

At the heart of our profession is our shared commitment to Care, Competency, and Integrity. These ethical values define who we are as pharmacists, guiding our decisions, shaping our relationships with patients, and underpinning the trust our communities place in us.

 

It is these three values that are the foundation of the Pharmacists Code of Ethics.

 

The Code of Ethics, last updated in 2017, must continue to evolve alongside the changing world in which we practice. As pharmacy practice continues to grow and diversify, the ethical challenges we face also become more complex. New models of care, greater prescribing authority, advances in digital health, and the growing role of pharmacists in compounding all bring opportunities, but also new responsibilities.

 

In our role as the custodians of the profession’s ethics, standards, and guidelines, PSA has embarked on a major project to revise and further develop the Code of Ethics – the first project delivered as part of the Strategic Agreement on Pharmacist Professional Practice.

 

This is not work we are doing alone. We are guided by a Project Advisory Group (PAG) made up of truly remarkable pharmacists and consumer representatives from across our profession and health sector, including:

  • Dr Ayomide (Mide) Ogundipe – PAG Chair; PSA Board Director
  • Professor Lisa Nissen – HERA Program Director, Health Workforce Optimisation, The University of Queensland
  • Associate Professor Sue Kirsa – Director of Pharmacy, Monash Health
  • Associate Professor Betty Chaar – Chair, Professionalism Committee, The University of Sydney, Fellow of the International Federation of Pharmacy and Chair of the FIP Ethics Expert Group and a Pharmacist Peer Reviewer for the Healthcare Complaints Commission NSW Australia.
  • Naomi Lim – Professional Officer, Pharmaceutical Defence Limited (PDL)
  • Toby Speare – Board Member, Pharmacy Board of Australia
  • Elsa Hietbrink – Director, Pharmacy Agreements & Governance, Dept of Health, Disability & Ageing
  • Radhika Jadav – Pharmacist Policy Officer, Pharmacy Guild of Australia
  • Associate Professor Bhavini Patel – Advanced Pharmacy Australia (AdPha) Leadership and Management Committee, Executive Director, Medicines Management, NT Health
  • Sebastian Harper – National President, National Australian Pharmacy Students’ Association (NAPSA)
  • Mike Stephens – National Aboriginal Community Controlled Health Organisation (NACCHO)
  • Dr Andreia Bruno-Tomé – Director, Research, Policy and Partnerships, Australian Pharmacy Council (APC)
  • Associate Professor Richard Matthews – Associate Professor of Medical Ethics, Bond University
  • Bente Hart – Remote and Isolated Pharmacist Association Australia (RIPAA)
  • Nathan Cruickshank – Professional Pharmacists Australia (PPA)
  • Nicky Bath – Consumer Representative
  • Prudence Buist – Consumer Representative

 

By updating our profession’s Code of Ethics, we are continuing to support all pharmacists to navigate the increasingly complex challenges we face. This breadth of expertise ensures the refreshed Code will be rigorous, practical, and responsive to the needs of our profession and the communities we serve.

 

Best wishes,

Associate Professor Fei Sim FPS
PSA National President

VIEW PROJECT ADVISORY GROUP
Share this page
Share this page

Federal Election Social Media Advocacy Kit

Click on the social media tiles to download. Use PSA’s suggested caption or write your own – and don’t forget to tag your local candidates!

Suggested caption: 

 

Pharmacists are providing more timely services in more convenient locations through expanded scope of practice. This election, I want to see strong support for pharmacists to continue providing better community healthcare.

 

Suggested caption: 

 

With government investment in full scope training for pharmacists, we can do more to keep patients out of emergency departments. This election I’m calling on (TAG LOCAL CANDIDATES) to back pharmacists, supporting us to support our communities.

Suggested caption: 

 

Patients are punished for accessing care from their local pharmacist, paying private prescription costs on PBS-listed medicines all because of who prescribed them. It’s time to give patients equitable access to medicines by allowing pharmacists to prescribe on the PBS.

Suggested caption: 

 

Every medicine-related incident is a chance to learn and improve safety. Tragically, this rarely happens outside the facility the incident occurs. A national system for doctors, pharmacists and patients to log incidents and share safety lessons is needed to protect patients.

Suggested caption: 

 

Older Australians deserve high-quality care. Pharmacists in aged care are reducing medicines harm and improving quality of life, but we need fair remuneration to attract the best pharmacists to this area of practice and continue delivering essential care.

Suggested caption: 

 

Patients miss out when pharmacists are capped, underfunded, or cut off from telehealth. Let’s lift HMR caps, bring back telehealth, and ensure funding keeps up with inflation so pharmacists can reach more people in need.

Suggested caption: 

 

Culturally safe care must include medicine safety. Pharmacists embedded in Aboriginal and Torres Strait Islander health services are making a real difference. It’s time for permanent funding – because the expertise and support of pharmacists should be available in all Aboriginal and Torres Strait Islander health services, not just a few.

Suggested caption: 

 

Pharmacists in general practice help patients manage medicines, avoid hospital, and get better health outcomes. Expanding WIP funding ensures more patients can benefit from our expertise as part of their healthcare team, right where they need it.

Suggested caption: 

 

As a pharmacist I see how my profession is stepping every single day. But I also see the challenges that prevent us from delivering the care our patients need.

 

This election, I’m calling on independents, major and minor parties to commit to supporting pharmacists so we can deliver safer and more accessible care for all Australians.

Share this page
Share this page

MMR Recognition of Prior Learning

Do you conduct Medication Management Reviews?

 

The Department of Health and Aged Care (the Department) has confirmed an extension to the Medication Management Review (MMR) transition period until 31 December 2025.

 

From 1 January 2026, pharmacists who have not obtained a new credential and MRN will not be able to claim payments for MMR services.

 

In short: If you don’t renew your credential prior to 1 January 2026, you won’t get paid. 

 

How do I obtain the new credential? 

 

To update your credential and receive a new MRN, you must undertake an Australian Pharmacy Council Accredited Medication Management Review (MMR) recognition of prior learning (RPL) process or training program. 

 

You can undertake the MMR RPL process with the Pharmaceutical Society of Australia. 

 

How much does it cost? 

 

PSA Professional Plus members can undertake the MMR RPL at no charge. There is a cost of $599 for pharmacists who are not PSA Professional Plus members.  

 

  • To become a PSA member, click here. 
  • To upgrade your membership to Professional Plus, please contact the Member Services Team on 1300 369 772 and select ‘Option 1’.  

 

When do I need to do this? 

 

To allow time for assessment and processing, it is strongly suggested that you enrol in the MMR RPL and submit your evidence by 26 October 2025.

 

Submissions made after this date will be assessed as soon as possible, however PSA cannot guarantee that new credentials will be provided before 1 January 2026. 

 

What do I need to do next? 

 

Step 1. Enrol in the MMR RPL 

 

 

Once you are enrolled you will have access to the MMR RPL module in the PSA portal, including the RPL and Gap Self-Assessment Tool. 

 

Step 2. Complete the PSA ‘RPL and Gap Self-Assessment Tool’ 

 

In the MMR module you will need to complete the RPL and Gap Self-Assessment Tool.

 

After completing:  

  1. If you believe you are competent in meeting the APC Performance Outcomes 1.1 and 4.2, you will need to collect evidence of your prior learning. 
  2. If you do not believe you are competent in meeting these outcomes, you will need to complete gap assessment activities (available in the MMR module), then proceed to step 3. 

 

Step 3. Submit your documentation 

 

The following documentation can be uploaded in the portal. This includes: 

  1. The completed RPL and Gap Self-Assessment Tool 
  2. A current CV/resume OR copies of at least two de-identified MMR reports OR details of PPA claims to demonstrate recency of practice. 
  3. A copy of your qualification e.g. AACP accreditation certificate or PSA certificate. 

As well as evidence of prior learning: 

  1. A completion certificate of the Deadly Pharmacist course (or approved alternative).
  2. A personal QI plan OR documentation of peer discussion of an MMR. 

What happens next? 

Your MMR RPL submission will be assessed and feedback provided. 

 

  • If all performance outcomes are met, you will receive access to a new MMR Credential certificate and medication review number (MRN) for claiming purposes. 
  • If performance outcomes are not met, you will be asked to provide further information.  

Frequently Asked Questions - MMR RPL

How much time do I need to allow to prepare my evidence?

This will vary depending on individual circumstances but please allow sufficient time to avoid rushing. The Deadly Pharmacist course, for example, requires 7 hours of learning.  

Once I submit my evidence, how long will it take for it to be assessed and feedback provided?

PSA are expecting a large volume of submissions in the months leading up to 1 January 2026.  

 

Complete MMR RPL submissions made before 19 October 2025 are guaranteed to be assessed and processed by the end of December 2025. 

Where can I complete the Deadly Pharmacist course or approved alternatives?

PSA’s Deadly Pharmacist training program can be completed at no cost. Alternatively, you can submit evidence of completion of cultural competence activities as part of a workplace assessment. 

What if I cannot provide evidence of prior learning?

If you cannot provide evidence of RPL, you can complete gap assessment activities. Please contact credentialing@psa.org.au for assistance. 

What if I submit my evidence after 19 October?

Submissions made after this date will be assessed as soon as possible, however PSA cannot guarantee that new credentials will be provided before 1 January 2026. 

Have other questions? Contact our friendly team at credentialing@psa.org.au and we will get back to you as soon as possible.

Share this page
Share this page

PSA Special General Meeting

Proposed change to PSA constitution

Notice is hereby given that a Special General Meeting (SGM) of the Members of the Pharmaceutical Society of Australia Limited (PSA) ABN 49 008 532 07. 

The PSA Board is excited to announce plans to acquire the Australian College of Pharmacy Pty Ltd (ACP), more commonly known as the Australasian College of Pharmacy, further enhancing PSA’s leadership in education and training for pharmacists and pharmacy assistants.  

ACP has been delivering education, training, and research programs to the pharmacy sector since 1976.  

To enable this momentus step forward, PSA members are being asked to support an amendment to the PSA Constitution at a Special General Meeting (SGM) on 19 February 2025.

For the acquisition to proceed, PSA members are asked to endorse a constitutional amendment in an upcoming Special General Meeting, providing for the appointment of four independent directors to complement PSA’s existing governance capabilities. These appointments will be skills-based, appointed by the former shareholders of the College, the Pharmacy Guild of Australia, the Pharmacy Guild of Australia NSW Branch, and Pharmacy Guild of Australia QLD Branch, bringing additional corporate knowledge, skills and expertise into PSA to ensure a successful transition.

The SGM will be held virtually and in person at the PSA Office in Canberra.

  • Date: 19 February 2025  
  • Time: Join by 5:45 pm for a 6 pm (AEDT) start  
  • Venue: Virtual and at PSA, Level 1/17 Denison St, Deakin ACT 2600 

 

Proxy voting has now closed. 

JOIN THE SPECIAL GENERAL MEETING (SGM) - 19 FEB 2025

To view the following information, please log into the PSA Member portal.

NOTICE OF SPECIAL GENERAL MEETING
EXPLANATORY NOTES
PROPOSED AMENDMENTS TO THE CONSTITUTION

Frequently Asked Questions

Why has the PSA Board decided to acquire ACP?

The decision to acquire ACP is part of the PSA Board’s broader plan to maximise member value through growth, expanding education opportunities for the profession, and securing a long-term, sustainable future for PSA as the premier training and education provider for pharmacists and pharmacy assistants and technicians.

 

Join the virtual member meeting on 4 February for further discussion with the PSA Board.

What does this mean for PSA members?

The constitutional change will allow PSA to acquire ACP.  If the acquisition is completed, PSA members can expect: 

 

  • reduced pressure to increase PSA membership fees 
  • access to a greater range of high quality CPD for pharmacists 
  • increased focus on education to meet the growing needs of pharmacists in all areas of practice, including transition to full scope of practice and emerging roles. 

 

Join the virtual member information session on Tuesday 4 February for further discussion with the PSA Board. 

What steps need to be taken for the acquisition to be approved?

Members present at an SGM on Wednesday 19 February 2025 will vote on a constitutional amendment.  75% of members present must vote in favour (FOR) of the amendment in order for it to pass. 

 

If you aren’t able to attend the SGM, register for proxy voting now

How do I vote?

Voting will take place during the SGM, which will be held virtually and in person at the PSA offices in Canberra on Wednesday 19 February 2025. 

 

If you aren’t able to attend the SGM, register your proxy vote now. 

What happens if I cannot attend the Special General Meeting on 19 February?

PSA members are able to nominate a proxy to submit their vote at the SGM.

What happens if PSA members vote down the amendment to the PSA constitution?

This would be a disappointing outcome for PSA and the profession as it would prevent the acquisition of ACP, and limit PSA’s ability to deliver education into the future.  

 

Join the virtual member information session on 4 February for further discussion with the PSA Board. Register now. 

What is proxy voting and how does it work?

A proxy vote allows you to appoint someone else to vote on your behalf at the Special General Meeting (SGM) if you cannot attend in person or virtually. The person you appoint (your “proxy”) can be:

 

  • Any individual of your choice (they do not need to be a PSA member).
  • The Chair of the meeting, by default, if you do not specify someone else or your appointed proxy does not attend.

 

Members can appoint a proxy using PSA’s secure online portal or by completing a proxy form. You can direct your proxy to vote FOR, AGAINST, or ABSTAIN on the resolution. If no voting directions are provided, your proxy will decide how to vote.

 

Proxy forms must be received by 6 pm AEDT on 18 February 2025.

If your appointed proxy does not attend or fails to vote, the Chair of the meeting (currently National President A/Prof Fei Sim) will act as your proxy and vote as directed on your form. If no directions are given, the Chair will vote at their discretion.

You can appoint a proxy in two ways:

 

  1. Online: Use the secure PSA portal to appoint a proxy and provide voting instructions.
  2. Hard Copy: Request a hard copy proxy form by emailing company.secretary@psa.org.au. Submit your completed form as directed before the deadline.

You can revoke or change your proxy appointment by submitting a new proxy form or by providing written notice to the Company Secretary before the proxy submission deadline.

 

Votes cast through a proxy can be either directed, or undirected.

 

  • Directed Votes: You specify how your proxy must vote (e.g., FOR, AGAINST, ABSTAIN). They are legally required to follow your instructions.
  • Undirected Votes: If you don’t provide instructions, your proxy (or the Chair) may vote or abstain at their discretion.

Where can I find more information?

 

You can email queries to: feedback@psa.org.au or company.secretary@psa.org.au

Share this page
Share this page

Routine Opioid Outcome Monitoring (ROOM) Tool

The Opioid Safety Toolkit also includes the Routine Opioid Outcome Monitoring (ROOM) Tool, a patient-reported outcomes measure designed to help patients and healthcare providers monitor clinical outcomes and identify risk factors associated with opioid use.

 

The ROOM Tool measures six key areas:  Analgesia (pain relief), Activity (functioning), Adverse effects, Addiction-related (or aberrant) behaviours, Affect (mood), and Alcohol (toxicity risk).

 

The ROOM Tool can be completed on paper or online, with a patient version and healthcare provider version available for download below. ROOM can be self-completed independently by the patient or with their pharmacist or prescriber. It takes less than five minutes to complete online (see button below) within the Toolkit, with online completion providing personalised information about outcomes, including identifying unmanaged pain, risks or adverse effects.  Pharmacists can utilise this tool to facilitate patient-centred discussions.

Image of ROOM Tool
DOWNLOAD ROOM TOOL - PATIENT VERSION
DOWNLOAD ROOM TOOL - PHARMACIST VERSION
COMPLETE ROOM TOOL ONLINE
Share this page
Share this page

Help your patients create an opioid safety plan

Using this online interactive resource, patients can create a personalised opioid safety plan (see button below) which can be shared with family members, carers or household members.  This plan helps patients identify opioid-related risks specific to their circumstances and provides guidance on recognising symptoms and treating opioid toxicity or overdose, including administering naloxone.

 

Naloxone has been shown to reduce opioid-related harms and is recommended for anyone on long-term prescription opioids to have in the home (referred to as ‘take-home naloxone’ – see button below).   Take-home naloxone is available as a nasal spray or intramuscular injection at no charge from many community pharmacies in Australia.  Any pharmacy can stock take-home naloxone, and any pharmacist can supply it without a prescription. You can claim reimbursement for naloxone you supply at https://www.ppaonline.com.au/

CREATE A PERSONALISED OPIOID SAFETY PLAN
ABOUT TAKE-HOME NALOXONE PROGRAM
Share this page
Share this page

Vaccination Webinar Series

PSA vaccination webinar series 2024

Throughout the unprecedented health challenges faced on a global scale in recent years, pharmacists have been increasingly recognised as essential frontline healthcare providers, playing an essential role in safeguarding public health. Starting in January 2024, the expansion of National Immunisation Program (NIP) vaccine delivery by pharmacists will increase their role in vaccine uptake and accessibility in Australia. To further equip and empower pharmacists with the knowledge and skills required to excel in their expansion of vaccination scope of practice, PSA will deliver a series of vaccination webinars.

 

1. National Immunisation Program (NIP) – 31 January 2024, 7.30pm – 8.30pm AEDT

WATCH RECORDED WEBINAR

2. Shingles – 21 February 2024, 7.00pm – 8.30pm AEDT.

WATCH RECORDED WEBINAR

3. Respiratory Syncytial Virus – 20 March 2024, 7.30pm – 8.30pm AEDT

WATCH RECORDED WEBINAR

4. Influenza – 17 April 2024, 7.30pm – 8.30pm AEST

WATCH RECORDED WEBINAR

5. Promoting Pharmacy Vaccination – Where do adolescents fit in? – 18 September 2024, 7.00pm – 8.00pm AEST

WATCH RECORDED WEBINAR

6. Childhood vaccination – 9 October 2024, 7.00pm – 8.15pm ADST

WATCH RECORDED WEBINAR

7. Boosting Pneumococcal Vaccination Rates in Pharmacy – 12 February 2025, 7.30pm – 9.00 pm ADST

WATCH RECORDED WEBINAR

Thank you to our participating partners

 

GSK-Seqirus-Sanofi logos image

Share this page
Share this page

Pharmacists in 2030

Published in 2019, Pharmacists in 2023 was the primary report into the future role of pharmacists across Australia’s health systems.

 

The report opened with statements highlighting the Australian health system’s universality, effectiveness, and efficiency. It also highlighted megatrends which would test these vital attributes and identified ways to unlock the potential of pharmacists to help respond to these trends. What was not identified in 2019 was the extent of acceleration for these trends which the COVID-19 pandemic would bring.

 

We have come a long way to achieving the vision set out in Pharmacists in 2023. As we reach the end date on this plan, it is time to reflect on these achievements and use its successes and lessons to forge the next plan for the profession as we head towards 2030. But there is much more to do.

 

 

Consultation has now closed. If you wish to provide feedback beyond the consultation, please email policy@psa.org.au

 

PSA has sought input from a range of stakeholders, including pharmacists, industry, governments, peak bodies, and other health professionals.

 

The next consultation phase seeks important feedback from the patients and customers we serve.

 

Your views are vital to shaping a future that serves the changing needs of our communities and supports the sustainability of the health sector.

 

Read the full consultation paper here and complete the consultation survey below.

Industry consultation open

September 2023

 

 

Consultation closes

December 2023

 

 

Review feedback, insights

January 2024

 

 

PSA member only briefing

February 2024

 

 

Targeted consumer consultation

Throughout 2024

 

 

Consumer insight report launch

June 2024

 

 

Pharmacists in 2030 launch

August 2024

Consumer voices strengthen PSA’s roadmap to 2030

Consumer voices strengthen PSA’s roadmap to 2030

18 December 2024   The Pharmaceutical Society of Australia (PSA) today release the Pharmacists in 2030: Strengthening consumer voices report, an addendum to the Pharmacists (…)

Read more
Scope of practice report confirms barriers to care and inefficiencies in current health system - time to implement all 18 recommendations

Scope of practice report confirms barriers to care and inefficiencies in current health system – time to implement all 18 recommendations

5 November 2024     The Pharmaceutical Society of Australia (PSA), the peak body representing 39,000 pharmacists across Australia’s health system, welcomes today’s release of (…)

Read more
Empowering pharmacists to meet Australia’s health needs

Empowering pharmacists to meet Australia’s health needs

25 September 2024 Marking World Pharmacists Day today (25 September), Australia’s peak body for pharmacists the Pharmaceutical Society of Australia (PSA) reaffirms the key actions (…)

Read more
Vision for Pharmacists in 2030 launched at PSA24

Vision for Pharmacists in 2030 launched at PSA24

2 August 2024   On the first day of its national conference PSA24, the Pharmaceutical Society of Australia (PSA) has launched its flagship vision for (…)

Read more
Load more
Share this page
Share this page

Protected: PSAmplified Hot Issues

This content is password protected. To view it please enter your password below:

Share this page

In the spirit of reconciliation, the Pharmaceutical Society of Australia (PSA) acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. We pay our respect to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today. We recognise that Aboriginal and Torres Strait Islander peoples were our first pharmacists.

CONTACT US | TERMS OF USE | PRIVACY

© 2025 Pharmaceutical Society of Australia Ltd. All rights reserved.
NOTICE: PSA's 1300 Contact Centre and Pharmacist Advice Line will exceptionally close for maintenance today Sept. 10th from 4:00PM AEST.
+